We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

PharmaGap Reports Significant Improvement in Efficacy of Enhanced GAP-107B8

PharmaGap Reports Significant Improvement in Efficacy of Enhanced GAP-107B8

PharmaGap Reports Significant Improvement in Efficacy of Enhanced GAP-107B8

PharmaGap Reports Significant Improvement in Efficacy of Enhanced GAP-107B8

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PharmaGap Reports Significant Improvement in Efficacy of Enhanced GAP-107B8"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PharmaGap Inc. reports significant improvement in efficacy using an enhanced version of its lead cancer drug GAP-107B8, along with a further update on progress toward clinical trials.

The Company has tested an enhanced version of GAP-107B8 and is seeing significantly increased efficacy for this unformulated peptide at lower doses from in-vitro and early in vivo results.

The Company has previously reported that using a liposomal formulation will permit it to achieve improved efficacy and widen the safety window for its lead drug GAP-107B8 in its original form.

A liposomal formulation of the enhanced peptide is currently being produced, with testing to follow in Q3. The combination of these two initiatives is expected to significantly broaden the Therapeutic Index for GAP-107B8 - the separation of effective dose from the higher doses at which toxicity appears - a key consideration for a successful clinical trial design.

Selection of the final peptide form and liposomal formulation to advance into efficacy studies is expected to be made in Q3 2011.

Robert McInnis, President and C.E.O. of the Company, commented that "The program that we have undertaken over the course of the past 9 months and which will continue to completion this year to enhance efficacy and safety of our lead drug compound will provide us with a significantly higher probability of approval of the clinical trial application and success in clinical trials. The short delay in the anticipated filing for clinical trial approval from Q3 2012 to Q4 2012, necessitated by this drug enhancement and formulation effort, will be more than offset by a much higher probability of success. Under the leadership and direction of our clinical development program by Dr. Ken Sokoll, and the work completed since his appointment as Vice President Clinical Development and Chief Operating Officer in September 2010, we are now provided with a much enhanced capability to meet the requirements to achieve clinical trial success, and accordingly a much higher degree of confidence in our ability to submit the clinical trial application by Q4 of 2012."

Other program elements
Work is underway at the Company's current manufacturer of peptide in order to optimize and scale-up the production of peptide that will proceed to cGMP ("current Good Manufacturing Practice") production of the peptide.

The Company has also received first results of testing in bladder cancer cell lines at a collaborator site. The early findings from in-vitro Colony Forming Assays ("CFA") in tumour cells has demonstrated that unformulated peptides can significantly reduce the survival of colonies in the two murine bladder cancer cell lines studied.

The early results from this study have also demonstrated that the enhanced GAP-107B8 peptide is more potent at lower concentrations. CFA assays provide useful information relevant to clinical development including the efficacy of the drug compound against cancer cells that metastasize and therapy-resistant cells that have the ability to re-populate tumours. Full details of these results will be announced when complete results are received and analyzed by the Company.

The Company is currently in contract discussions with an independent Contract Research Organization to expand and accelerate the investigation of liposomal formulations and unformulated versions of GAP-107B8 in in vivo models of bladder cancer, and expects to be able to start this program in early Q3 2011.

Additional in vivo studies in ovarian cancer models will take place in Q3/Q4 using liposomal formulations of GAP-107B8 peptides. Results of this testing will be critical to the choice of final formulation of GAP-107B8 and the cancer target to proceed to clinical trials.

With the significance and extent of new data generated, specifically with respect to peptides and liposomal formulations, the Company is developing and filing additional patents in order to generate new and valuable Intellectual Property Rights for its lead cancer drug program.

Discussions have commenced and will continue through 2011 with Clinical Trial Contract Research Organizations. Past performance in accruing patients for bladder and ovarian cancer trials and access to key oncology leaders in these cancers will be a key determining factor in this selection, to be made in early 2012.